|
1
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Peters L and Meister G: Argonaute
proteins: mediators of RNA silencing. Mol Cell. 26:611–623. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Carthew RW and Sontheimer EJ: Origins and
mechanisms of miRNAs and siRNAs. Cell. 136:642–655. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jansson MD and Lund AH: MicroRNA and
cancer. Mol Oncol. 6:590–610. 2012. View Article : Google Scholar
|
|
5
|
Chen PS, Su JL and Hung MC: Dysregulation
of microRNAs in cancer. J Biomed Sci. 19:902012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar
|
|
7
|
Hammond SM: MicroRNAs as tumor
suppressors. Nat Genet. 39:582–583. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Qin X, Yan L, Zhao X, Li C and Fu Y:
microRNA-21 overexpression contributes to cell proliferation by
targeting PTEN in endometrioid endometrial cancer. Oncol Lett.
4:1290–1296. 2012.PubMed/NCBI
|
|
9
|
Rather MI, Nagashri MN, Swamy SS, Gopinath
KS and Kumar A: Oncogenic microRNA-155 downregulates tumor
suppressor CDC73 and promotes oral squamous cell carcinoma cell
proliferation: implications for cancer therapeutics. J Biol Chem.
288:608–618. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu L, Yu X, Guo X, et al: miR-143 is
downregulated in cervical cancer and promotes apoptosis and
inhibits tumor formation by targeting Bcl-2. Mol Med Rep.
5:753–760. 2012.PubMed/NCBI
|
|
11
|
Frampton AE, Krell J, Jacob J, Stebbing J,
Castellano L and Jiao LR: Loss of miR-126 is crucial to pancreatic
cancer progression. Expert Rev Anticancer Ther. 12:881–884. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu X, Jiang L, Wang A, Yu J, Shi F and
Zhou X: MicroRNA-138 suppresses invasion and promotes apoptosis in
head and neck squamous cell carcinoma cell lines. Cancer Lett.
286:217–222. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Link MP: Osteosarcoma in adolescents and
young adults: new developments and controversies. Commentary on the
use of presurgical chemotherapy. Cancer Treat Res. 62:383–385.
1993.PubMed/NCBI
|
|
14
|
Jaffe N: Osteosarcoma: review of the past,
impact on the future. The American experience. Cancer Treat Res.
152:239–262. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ferguson WS and Goorin AM: Current
treatment of osteosarcoma. Cancer Invest. 19:292–315. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Novello C, Pazzaglia L, Cingolani C, et
al: miRNA expression profile in human osteosarcoma: role of miR-1
and miR-133b in proliferation and cell cycle control. Int J Oncol.
42:667–675. 2013.PubMed/NCBI
|
|
17
|
Zhao H, Guo M, Zhao G, et al: miR-183
inhibits the metastasis of osteosarcoma via downregulation of the
expression of Ezrin in F5M2 cells. Int J Mol Med. 30:1013–1020.
2012.PubMed/NCBI
|
|
18
|
Yan K, Gao J, Yang T, et al: MicroRNA-34a
inhibits the proliferation and metastasis of osteosarcoma cells
both in vitro and in vivo. PLoS One. 7:e337782012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fan L, Wu Q, Xing X, Wei Y and Shao Z:
MicroRNA-145 targets vascular endothelial growth factor and
inhibits invasion and metastasis of osteosarcoma cells. Acta
Biochim Biophys Sin. 44:407–414. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Osaki M, Takeshita F, Sugimoto Y, et al:
MicroRNA-143 regulates human osteosarcoma metastasis by regulating
matrix metalloprotease-13 expression. Mol Ther. 19:1123–1130. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cho HM, Jeon HS, Lee SY, et al:
microRNA-101 inhibits lung cancer invasion through the regulation
of enhancer of zeste homolog 2. Exp Ther Med. 2:963–967.
2011.PubMed/NCBI
|
|
22
|
Wang HJ, Ruan HJ, He XJ, et al:
MicroRNA-101 is downregulated in gastric cancer and involved in
cell migration and invasion. Eur J Cancer. 46:2295–2303. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang R, Wang HB, Hao CJ, et al: MiR-101 is
involved in human breast carcinogenesis by targeting Stathmin1.
PLoS One. 7:e461732012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Smits M, Nilsson J, Mir SE, et al: miR-101
is downregulated in glioblastoma resulting in EZH2-induced
proliferation, migration, and angiogenesis. Oncotarget. 1:710–720.
2010.PubMed/NCBI
|
|
25
|
He LJ, Cai MY, Xu GL, et al: Prognostic
significance of overexpression of EZH2 and H3k27me3 proteins in
gastric cancer. Asian Pac J Cancer Prev. 13:3173–3178. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ren G, Baritaki S, Marathe H, et al:
Polycomb protein EZH2 regulates tumor invasion via the
transcriptional repression of the metastasis suppressor RKIP in
breast and prostate cancer. Cancer Res. 72:3091–3104. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rao ZY, Cai MY, Yang GF, et al: EZH2
supports ovarian carcinoma cell invasion and/or metastasis via
regulation of TGF-beta1 and is a predictor of outcome in ovarian
carcinoma patients. Carcinogenesis. 31:1576–1583. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen X, Yang TT, Wang W, et al:
Establishment and characterization of human osteosarcoma cell lines
with different pulmonary metastatic potentials. Cytotechnology.
61:37–44. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Negrini M and Calin GA: Breast cancer
metastasis: a microRNA story. Breast Cancer Res. 10:2032008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Watahiki A, Wang Y, Morris J, et al:
MicroRNAs associated with metastatic prostate cancer. PLoS One.
6:e249502011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wada T, Isu K, Takeda N, Usui M, Ishii S
and Yamawaki S: A preliminary report of neoadjuvant chemotherapy
NSH-7 study in osteosarcoma: preoperative salvage chemotherapy
based on clinical tumor response and the use of granulocyte
colony-stimulating factor. Oncology. 53:221–227. 1996. View Article : Google Scholar
|
|
32
|
Sauvageau M and Sauvageau G: Polycomb
group proteins: multi-faceted regulators of somatic stem cells and
cancer. Cell Stem Cell. 7:299–313. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Varambally S, Dhanasekaran SM, Zhou M, et
al: The polycomb group protein EZH2 is involved in progression of
prostate cancer. Nature. 419:624–629. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hussein YR, Sood AK, Bandyopadhyay S, et
al: Clinical and biological relevance of enhancer of zeste homolog
2 in triple-negative breast cancer. Hum Pathol. 43:1638–1644. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Changchien YC, Tatrai P, Papp G, et al:
Poorly differentiated synovial sarcoma is associated with high
expression of enhancer of zeste homologue 2 (EZH2). J Transl Med.
10:2162012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang H, Albadine R, Magheli A, et al:
Increased EZH2 protein expression is associated with invasive
urothelial carcinoma of the bladder. Urol Oncol. 30:428–433. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fluge Ø, Gravdal K, Carlsen E, et al:
Expression of EZH2 and Ki-67 in colorectal cancer and associations
with treatment response and prognosis. Br J Cancer. 101:1282–1289.
2009.PubMed/NCBI
|
|
38
|
Guo SQ and Zhang YZ: Overexpression of
enhancer of zests homolog 2 in lymphoma. Chin Med J. 125:3735–3739.
2012.PubMed/NCBI
|
|
39
|
Sasaki H, Setoguchi T, Matsunoshita Y, Gao
H, Hirotsu M and Komiya S: The knock-down of overexpressed EZH2 and
BMI-1 does not prevent osteosarcoma growth. Oncol Rep. 23:677–684.
2010.PubMed/NCBI
|
|
40
|
Tong ZT, Cai MY, Wang XG, et al: EZH2
supports nasopharyngeal carcinoma cell aggressiveness by forming a
co-repressor complex with HDAC1/HDAC2 and Snail to inhibit
E-cadherin. Oncogene. 31:583–594. 2012.PubMed/NCBI
|
|
41
|
Liu DC and Yang ZL: Overexpression of EZH2
and loss of expression of PTEN is associated with invasion,
metastasis, and poor progression of gallbladder adenocarcinoma.
Pathol Res Pract. 207:472–478. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Alford SH, Toy K, Merajver SD and Kleer
CG: Increased risk for distant metastasis in patients with familial
early-stage breast cancer and high EZH2 expression. Breast Cancer
Res Treat. 132:429–437. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Song QC, Shi ZB, Zhang YT, et al:
Downregulation of microRNA-26a is associated with metastatic
potential and the poor prognosis of osteosarcoma patients. Oncol
Rep. 31:1263–1270. 2014.PubMed/NCBI
|
|
44
|
Sakurai T, Bilim VN, Ugolkov AV, et al:
The enhancer of zeste homolog 2 (EZH2), a potential therapeutic
target, is regulated by miR-101 in renal cancer cells. Biochem
Biophys Res Commun. 422:607–614. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Varambally S, Cao Q, Mani RS, et al:
Genomic loss of microRNA-101 leads to overexpression of histone
methyltransferase EZH2 in cancer. Science. 322:1695–1699. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Banerjee R, Mani RS, Russo N, et al: The
tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2
overexpression in invasive squamous cell carcinoma. Oncogene.
30:4339–4349. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Friedman JM, Liang G, Liu CC, et al: The
putative tumor suppressor microRNA-101 modulates the cancer
epigenome by repressing the polycomb group protein EZH2. Cancer
Res. 69:2623–2629. 2009. View Article : Google Scholar : PubMed/NCBI
|
